Requests that the FDA declare that the proposed drug products, Pregabalin Extended-Release Tablets, 247.5 mg, 495 mg and 660 mg, are suitable for submission as an ANDA
🏛 Food and Drug Administration (FDA)FDA-2026-P-1792
Documents
2
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
- Other· Feb 19, 2026No comment period